PERIPHERALLY DELIVERED GLUTAMIC ACID DECARBOXYLASE GENE THERAPY FOR SPINAL CORD INJURY PAIN

1 . (canceled)

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . (canceled)

6 . (canceled)

7 . (canceled)

8 . (canceled)

9 . (canceled)

10 . (canceled)

11 . (canceled)

12 . (canceled)

13 . A method of treating spinal cord injury pain or peripheral neuropathic pain in a mammal comprising: administering to a mammal experiencing spinal cord injury pain or peripheral neuropathic pain a vector comprising a nucleotide sequence encoding a glutamic acid decarboxylase (GAD) protein in an amount effective to treat spinal cord injury pain or peripheral neuropathic pain.

14 . The method of claim 13 , wherein the vector is a viral vector.

15 . (canceled)

16 . (canceled)

17 . The method of claim 13 , wherein the vector is a non-viral vector.

18 . The method of claim 13 , wherein the GAD protein is GAD67.

19 . The method of claim 13 , wherein the nucleotide sequence encoding the GAD protein is operably linked to a promoter.

20 . The method of claim 19 , wherein the promoter is a human cytomegalovirus immediate early promoter (HCMV IEp).

21 . (canceled)

22 . (canceled)

23 . (canceled)

24 . (canceled)

25 . (canceled)

26 . The method of claim 13 , wherein the vector is peripherally administered.

27 . The method of claim 26 , wherein the vector is administered to an appendage.

28 . The method of claim 27 , wherein the appendage is below a level of spinal cord injury.

29 . The method of claim 13 , wherein the mammal is a human.

30 . (canceled)

31 . (canceled)

32 . (canceled)

33 . (canceled)

34 . (canceled)

35 . (canceled)

36 . (canceled)

37 . (canceled)

38 . (canceled)

39 . The method of claim 13 , wherein the GAD protein is GAD25.

40 . The method of claim 13 , wherein the GAD protein is GAD65.

41 . The method of claim 14 , wherein the viral vector is a retroviral vector.

42 . The method of claim 14 , wherein the viral vector is a parvovirus based vector.

43 . The method of claim 14 , wherein the viral vector is an adeno-associated virus (AAV) based vector.

44 . The method of claim 14 , wherein the viral vector is an adenovirus-based vector.

45 . The method of claim 14 , wherein the viral vector is a chimeric viral vector.

46 . The method of claim 14 , wherein the viral vector is a herpes virus based vector.

47 . The method of claim 46 , wherein the herpes virus based vector is a non-amplicon herpes simplex virus (HSV) based vector.

48 . The method of claim 47 , wherein the vector is deficient for at least one essential HSV gene.

49 . The method of claim 48 , wherein the essential HSV gene is an early, immediate-early, or late HSV gene.

50 . The method of claim 49 , wherein the vector is deficient for an immediate early gene is selected from the group consisting of: ICP4, ICP22, ICP27, ICP47, and a combination thereof.

51 . The method of claim 47 , wherein the vector comprises extended deletions of ICP4, ICP27, and the deletion of UL55.

52 . The method of claim 47 , wherein the vector is replication deficient.